An open-label, safety, pharmacokinetic and pharmacodynamic study of multiple doses of GW572016 [lapatinib] to examine the inhibition of EGFR/ERB2 phosphorylation in cancer patients with solid tumour
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2007
At a glance
- Drugs Lapatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 28 Jun 2007 New trial record.